The FDA has required the addition of information about an increased risk of nonmelanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) to the labels of products containing the diuretic hydrochlorothiazide.1

The labeling change was based on a review of published observational studies and on the results of an observational study conducted in the FDA's Sentinel system. In a national case-control study in Denmark, use of hydrochlorothiazide was associated with an increased risk of BCC and SCC (adjusted odds ratio [OR] 1.08 for BCC and 1.75 for SCC). The increase in risk correlated with the cumulative dose of the drug; among patients who received a lifetime...  Continue reading

More from Issue 1611
Previous Issue: 1610      November 2, 2020
Coming Soon
Drugs for Asthma
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
Ofatumumab (Kesimpta) for Multiple Sclerosis
An EUA for Baricitinib for COVID-19
An EUA for Casirivimab and Imdevimab - A Monoclonal Antibody Combination for COVID-19
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
Advance Release

 An EUA for Bamlanivimab — A Monoclonal Antibody for COVID-19 

The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at ... Continue reading